Weight Loss Simulator for GLP-1 users.
See your projected weight loss on medication and discover the difference healthy habits make in keeping it off.
Toggle to compare V-curve vs L-curve
Frequently asked questions.
Clinical trials show average weight loss of about 15% of body weight on semaglutide (Ozempic/Wegovy) and about 20% on tirzepatide (Mounjaro/Zepbound) over 12 to 18 months. Individual results vary based on starting weight, diet, exercise, and other factors.
The V-to-L pattern describes two weight loss trajectories. The V-shape is when people lose weight on medication but regain most of it after stopping, forming a V on a chart. The L-shape is when people build healthy habits during treatment, so their weight stays down after tapering off, forming an L shape.
Studies show that about two-thirds of weight lost is regained within one year of stopping GLP-1 medications if no lifestyle changes are maintained. However, people who build sustainable nutrition and exercise habits during treatment are significantly more likely to maintain their weight loss.
The key is building habits while the medication makes it easier. Focus on hitting your protein goals, establishing a regular exercise routine, tracking your meals, and gradually tapering off rather than stopping abruptly. Apps like Phaze help you build these habits systematically.
Build the habits that keep it off.
Phaze helps you build sustainable nutrition, exercise, and tracking habits while your medication makes it easier. Turn your V into an L.
Download FreeThis simulator provides estimates based on published clinical averages. Individual results vary significantly. Consult your healthcare provider before making changes to your medication or treatment plan.